A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib

Bristol-Myers Squibb150 enrolled

Overview

The purpose of this study is to determine real-world patient-reported outcomes with fedratinib (FEDR) therapy for myelofibrosis (MF) in the real-world (RW) setting.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Myelofibrosis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with Primary myelofibrosis (PMF), post- Essential thrombocythemia (ET) Myelofibrosis (MF), or post- Polycythemia vera (PV) MF * Treated with FEDR and initiated treatment after 16 August 2019. * Received prior treatment with RUX. * Had spleen assessed at time of initiation of FEDR by palpation. * Able to read and speak English * Willing to provide informed consent * Willing to provide permission to the site to release her/his medical information to the study investigators according to the study-specific eCRF * Willing to complete the baseline survey prior to first FEDR Exclusion Criteria: * Past or current participant in any FEDR-related clinical trial

Locations (1)

Cardinal Health Specialty Solutions

Dublin, Ohio, United States

Outcomes

Primary Outcomes

Percentage change in Total Symptom Score (TSS) assessed by Myelofibrosis Symptom Assessment Form (MFSAF)

Time frame: Percentage change in Total Symptom Score (TSS) assessed by Myelofibrosis Symptom Assessment Form (MFSAF)

Absolute change in TSS assessed by MFSAF